DOI: 10.21276/sajp.2018.7.2.6

Pages: 99-104

Cervical cancer is one of the primary cancers affecting women worldwide. It is another term used for malignant neoplasm originating from the cells of cervix uteri. Cervical cancer is the 2nd most frequent cancer among women globally, among a predictable 528,000 latest cases along with 266,000 deaths between women every year. The culprit behind this disease is Human papillomavirus. About 70% of cervical cancers are caused by type 16 and 18 HPV. The occurrence of HPV is greater in countries where cervical cancer burden is high. Its prevalence depends upon genetic and non-genetic factors. The latter include diet, exercise, lifestyle etc. The treatment for cervical cancer varies among countries due to lack of expertise in radical pelvic surgery. Many times, radiotherapy is combined with chemotherapy for effective cure. Recent advances in the areas of surgery, radiotherapy, and chemotherapy for the treatment of cervical cancer have significantly reduced patient fatality rate with better quality of life. The development and implementation of a combination of CT/RT have escalated survival rates in many cases. Bevacizumab in chemotherapy has also improved survival rates. But despite so much progress made in recent years